Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic AtrophyGlobeNewsWire • 04/05/24
Ocugen, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ocugen (OCGN)Accesswire • 04/04/24
Ocugen, Inc. (OCGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire • 04/03/24
ATTENTION Ocugen, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 04/03/24
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023GlobeNewsWire • 04/02/24
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt DiseaseGlobeNewsWire • 04/01/24
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023GlobeNewsWire • 04/01/24
Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar RevenuesSeeking Alpha • 03/19/24
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410GlobeNewsWire • 03/13/24
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall StreetThe Motley Fool • 03/07/24
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410STGlobeNewsWire • 02/22/24